一种用于鉴别诊断EM/FEM的试剂盒

• Format: Patent
• Language: Chinese
• Published: 15.11.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; TESTING; VINEGAR; WINE

本发明涉及生物技术领域，尤其涉及鉴别卵巢子宫内膜异位症/卵巢其他良性肿瘤试剂及其应用。本发明提供检测受试者样本中生物标志物含量的试剂在制备用于卵巢子宫内膜异位症/卵巢其他良性肿瘤鉴的鉴别诊断产品中的应用，所述生物标志物包括CA125、SELL、LILRA3、IGKC和/或DSC2。本发明提供了一种用于卵巢子宫内膜异位症/卵巢其他良性肿瘤鉴别诊断的标志物，CA125、SELL、LILRA3、IGKC和/或DSC2，可用于制备鉴别诊断EM/FEM的检测试剂盒等，其鉴别特异性好，灵敏度高。采用该试剂盒可以提高临床EM/FEM鉴别诊断的准确性，从而使患者获得更加准确的治疗措施，获得更佳的治疗效果。 The invention relates to the technical field of biology, in particular to a reagent for identifying ovarian endometriosis/other ovarian benign tumors and application of the reagent. The invention provides application of a reagent for detecting the content of a biomarker in a subject sample in preparation of a product for differential diagnosis of ovarian endometriosis/other ovarian benign tumors. The biomarkers comprise CA125, SELL, LILRA3, IGKC and/or DSC2 (Differentiated Sequence Cells). The invention also provides a marker CA125, SELL, LILRA3, IGKC and/or DSC2 for differential diagnosis of ovarian endometriosis/other ovarian benign tumors, can be used for preparing a detection kit and the like for differential di